Carcinoembryonic Antigen Market Size Report, 2032

Carcinoembryonic Antigen (CEA) Market – By Application, By Gender, End-user – Global Forecast, 2024 – 2032

Report Content

Chapter 1&nbsp;&nbsp;&nbsp;Methodology &amp; Scope

1.1&nbsp;&nbsp;&nbsp; Market segmentation

1.2&nbsp;&nbsp;&nbsp; Research design

1.2.1&nbsp;&nbsp;&nbsp; Research approach

1.2.2&nbsp;&nbsp;&nbsp; Data collection methods

1.3&nbsp;&nbsp;&nbsp; Base estimates and calculations

1.3.1&nbsp;&nbsp;&nbsp; Base year calculations

1.3.2&nbsp;&nbsp;&nbsp; Key trends for market estimates

1.4&nbsp;&nbsp;&nbsp; Forecast model

1.5&nbsp;&nbsp;&nbsp; Primary research and validation

1.5.1&nbsp;&nbsp;&nbsp; Primary sources

1.5.2&nbsp;&nbsp;&nbsp; Data mining sources

Chapter 2&nbsp;&nbsp;&nbsp;Executive Summary 

2.1&nbsp;&nbsp;&nbsp; Industry 3600 synopsis

Chapter 3&nbsp;&nbsp;&nbsp;Industry Insights 

3.1&nbsp;&nbsp;&nbsp; Industry ecosystem

3.2&nbsp;&nbsp;&nbsp; Industry impact forces

3.2.1&nbsp;&nbsp;&nbsp; Growth drivers

3.2.1.1&nbsp;&nbsp;&nbsp;Rising in cancer prevalence

3.2.1.2&nbsp;&nbsp;&nbsp;Growing demand for minimally invasive diagnostic procedures

3.2.1.3&nbsp;&nbsp;&nbsp;Recent technological advancements in carcinoembryonic antigen diagnostics

3.2.1.4&nbsp;&nbsp;&nbsp;Increasing per capita healthcare expenditure

3.2.2&nbsp;&nbsp;&nbsp; Industry pitfalls &amp; challenges

3.2.2.1&nbsp;&nbsp;&nbsp;Inability to detect early-stage cancer

3.2.2.2&nbsp;&nbsp;&nbsp;Lack of awareness regarding the application of carcinoembryonic antigen tests

3.3&nbsp;&nbsp;&nbsp; Growth potential analysis

3.4&nbsp;&nbsp;&nbsp; Regulatory landscape

3.4.1&nbsp;&nbsp;&nbsp; U.S.

3.4.2&nbsp;&nbsp;&nbsp; Europe

3.5&nbsp;&nbsp;&nbsp; Global incidence of top cancers, by region, 2023

3.5.1&nbsp;&nbsp;&nbsp; North America cancer incidence

3.5.2&nbsp;&nbsp;&nbsp; Europe cancer incidence

3.5.3&nbsp;&nbsp;&nbsp; Asia Pacific cancer incidence

3.5.4&nbsp;&nbsp;&nbsp; Latin America cancer incidence

3.5.5&nbsp;&nbsp;&nbsp; Middle East &amp; Africa cancer incidence

3.6&nbsp;&nbsp;&nbsp; Clinical studies landscape

3.7&nbsp;&nbsp;&nbsp; Porter&#39;s analysis

3.8&nbsp;&nbsp;&nbsp; PESTEL analysis

Chapter 4&nbsp;&nbsp;&nbsp;Competitive Landscape, 2023

4.1&nbsp;&nbsp;&nbsp; Introduction

4.1.1&nbsp;&nbsp;&nbsp; F. Hoffmann-La Roche Ltd.

4.1.2&nbsp;&nbsp;&nbsp; Quest Diagnostics Incorporated

4.1.3&nbsp;&nbsp;&nbsp; Thermo Fisher Scientific Inc.

4.2&nbsp;&nbsp;&nbsp; Competitive analysis of major market players

4.3&nbsp;&nbsp;&nbsp; Company matrix analysis

4.4&nbsp;&nbsp;&nbsp; Competitive positioning matrix

4.5&nbsp;&nbsp;&nbsp; Strategy dashboard

Chapter 5&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Application, 2021 &ndash; 2032 ($ Mn)

5.1&nbsp;&nbsp;&nbsp; Key trends

5.2&nbsp;&nbsp;&nbsp; Gastrointestinal cancer

5.2.1&nbsp;&nbsp;&nbsp; Colorectal cancer

5.2.2&nbsp;&nbsp;&nbsp; Pancreatic cancer

5.2.3&nbsp;&nbsp;&nbsp; Liver cancer

5.2.4&nbsp;&nbsp;&nbsp; Stomach cancer

5.2.5&nbsp;&nbsp;&nbsp; Esophageal cancer

5.2.6&nbsp;&nbsp;&nbsp; Gall bladder cancer

5.2.7&nbsp;&nbsp;&nbsp; Anal cancer

5.3&nbsp;&nbsp;&nbsp; Breast cancer

5.4&nbsp;&nbsp;&nbsp; Lung cancer

5.5&nbsp;&nbsp;&nbsp; Ovarian cancer

5.6&nbsp;&nbsp;&nbsp; Prostate cancer

5.7&nbsp;&nbsp;&nbsp; Thyroid cancer

Chapter 6&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Gender, 2021 &ndash; 2032 ($ Mn)

6.1&nbsp;&nbsp;&nbsp; Key trends

6.2&nbsp;&nbsp;&nbsp; Male

6.3&nbsp;&nbsp;&nbsp; Female

Chapter 7&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By End-user, 2021 &ndash; 2032 ($ Mn)

7.1&nbsp;&nbsp;&nbsp; Key trends

7.2&nbsp;&nbsp;&nbsp; Hospitals

7.3&nbsp;&nbsp;&nbsp; Diagnostic laboratories

7.4&nbsp;&nbsp;&nbsp; Oncology clinics

7.5&nbsp;&nbsp;&nbsp; Research centers and academic institutes

Chapter 8&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Region, 2021 &ndash; 2032 ($ Mn)

8.1&nbsp;&nbsp;&nbsp; Key trends

8.2&nbsp;&nbsp;&nbsp; North America

8.2.1&nbsp;&nbsp;&nbsp; U.S.

8.2.2&nbsp;&nbsp;&nbsp; Canada

8.3&nbsp;&nbsp;&nbsp; Europe

8.3.1&nbsp;&nbsp;&nbsp; Germany

8.3.2&nbsp;&nbsp;&nbsp; UK

8.3.3&nbsp;&nbsp;&nbsp; France

8.3.4&nbsp;&nbsp;&nbsp; Spain

8.3.5&nbsp;&nbsp;&nbsp; Italy

8.3.6&nbsp;&nbsp;&nbsp; Poland

8.3.7&nbsp;&nbsp;&nbsp; Russia

8.3.8&nbsp;&nbsp;&nbsp; Sweden

8.3.9&nbsp;&nbsp;&nbsp; Switzerland

8.3.10&nbsp;&nbsp;&nbsp; Netherlands

8.3.11&nbsp;&nbsp;&nbsp; Rest of Europe

8.4&nbsp;&nbsp;&nbsp; Asia Pacific

8.4.1&nbsp;&nbsp;&nbsp; China

8.4.2&nbsp;&nbsp;&nbsp; Japan

8.4.3&nbsp;&nbsp;&nbsp; India

8.4.4&nbsp;&nbsp;&nbsp; Australia

8.4.5&nbsp;&nbsp;&nbsp; South Korea

8.4.6&nbsp;&nbsp;&nbsp; New Zealand

8.4.7&nbsp;&nbsp;&nbsp; Malaysia

8.4.8&nbsp;&nbsp;&nbsp; Singapore

8.4.9&nbsp;&nbsp;&nbsp; Indonesia

8.4.10&nbsp;&nbsp;&nbsp; Philippines

8.4.11&nbsp;&nbsp;&nbsp; Rest of Asia Pacific

8.5&nbsp;&nbsp;&nbsp; Latin America

8.5.1&nbsp;&nbsp;&nbsp; Brazil

8.5.2&nbsp;&nbsp;&nbsp; Mexico

8.5.3&nbsp;&nbsp;&nbsp; Argentina

8.5.4&nbsp;&nbsp;&nbsp; Columbia

8.5.5&nbsp;&nbsp;&nbsp; Peru

8.5.6&nbsp;&nbsp;&nbsp; Rest of Latin America

8.6&nbsp;&nbsp;&nbsp; Middle East and Africa

8.6.1&nbsp;&nbsp;&nbsp; Saudi Arabia

8.6.2&nbsp;&nbsp;&nbsp; South Africa

8.6.3&nbsp;&nbsp;&nbsp; UAE

8.6.4&nbsp;&nbsp;&nbsp; Rest of Middle East and Africa

Chapter 9&nbsp;&nbsp;&nbsp;Company Profiles 

9.1&nbsp;&nbsp;&nbsp; Abcam Limited

9.2&nbsp;&nbsp;&nbsp; AdvaCare Pharma

9.3&nbsp;&nbsp;&nbsp; Aviva Systems Biology Corporation

9.4&nbsp;&nbsp;&nbsp; Boster Biological Technology

9.5&nbsp;&nbsp;&nbsp; Creative Diagnostics

9.6&nbsp;&nbsp;&nbsp; Diazyme Laboratories Inc.

9.7&nbsp;&nbsp;&nbsp; F. Hoffmann-La Roche Ltd.

9.8&nbsp;&nbsp;&nbsp; Medix Biochemica

9.9&nbsp;&nbsp;&nbsp; Omega Diagnostics Ltd.

9.10&nbsp;&nbsp;&nbsp; RayBiotech, Inc.

9.11&nbsp;&nbsp;&nbsp; Thermo Fisher Scientific Inc.

9.12&nbsp;&nbsp;&nbsp; Quest Diagnostics Incorporated

&nbsp;&nbsp;&nbsp;

Carcinoembryonic Antigen (CEA) Market

Inquiry Before Buying